Equities research analysts expect Albemarle Co. (NYSE:ALB) to announce earnings of $1.42 per share for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Albemarle’s earnings, with the highest EPS estimate coming in at $1.54 and the lowest estimate coming in at $1.35. Albemarle reported earnings of $1.36 per share during the same quarter last year, which indicates a positive year over year growth rate of 4.4%. The company is scheduled to announce its next earnings report on Tuesday, August 6th.
On average, analysts expect that Albemarle will report full year earnings of $6.22 per share for the current year, with EPS estimates ranging from $6.10 to $6.38. For the next year, analysts anticipate that the business will post earnings of $6.77 per share, with EPS estimates ranging from $4.66 to $7.47. Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that follow Albemarle.
Albemarle (NYSE:ALB) last posted its quarterly earnings data on Wednesday, May 8th. The specialty chemicals company reported $1.23 EPS for the quarter, topping the consensus estimate of $1.21 by $0.02. Albemarle had a return on equity of 15.53% and a net margin of 20.54%. The firm had revenue of $832.06 million for the quarter, compared to the consensus estimate of $827.94 million. During the same quarter last year, the company earned $1.30 earnings per share. The business’s revenue for the quarter was up 1.3% compared to the same quarter last year.
In other Albemarle news, SVP Deeanne J. Marlow purchased 1,000 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The stock was purchased at an average cost of $70.85 per share, with a total value of $70,850.00. Following the purchase, the senior vice president now owns 1,000 shares of the company’s stock, valued at $70,850. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.02% of the stock is currently owned by company insiders.
Several hedge funds have recently modified their holdings of the stock. Icon Wealth Partners LLC bought a new stake in Albemarle during the 1st quarter valued at $25,000. Pinnacle Bank purchased a new position in shares of Albemarle in the 4th quarter valued at $27,000. Alpha Omega Wealth Management LLC increased its holdings in shares of Albemarle by 125.0% in the 1st quarter. Alpha Omega Wealth Management LLC now owns 360 shares of the specialty chemicals company’s stock valued at $30,000 after acquiring an additional 200 shares during the period. Thor Advisors LLC purchased a new position in shares of Albemarle in the 1st quarter valued at $37,000. Finally, QCM Cayman Ltd. increased its holdings in shares of Albemarle by 241.6% in the 1st quarter. QCM Cayman Ltd. now owns 60,800 shares of the specialty chemicals company’s stock valued at $70,000 after acquiring an additional 43,000 shares during the period. 89.77% of the stock is owned by hedge funds and other institutional investors.
Shares of NYSE ALB traded up $0.02 during trading on Thursday, hitting $70.51. The company had a trading volume of 36,508 shares, compared to its average volume of 1,466,153. The company has a 50 day simple moving average of $68.83. The company has a quick ratio of 0.96, a current ratio of 1.55 and a debt-to-equity ratio of 0.36. Albemarle has a 12 month low of $63.10 and a 12 month high of $108.74. The company has a market capitalization of $7.48 billion, a price-to-earnings ratio of 12.86, a P/E/G ratio of 0.74 and a beta of 1.63.
The firm also recently declared a quarterly dividend, which was paid on Monday, July 1st. Investors of record on Friday, June 14th were paid a dividend of $0.3675 per share. This represents a $1.47 dividend on an annualized basis and a dividend yield of 2.08%. The ex-dividend date was Thursday, June 13th. Albemarle’s dividend payout ratio is currently 26.82%.
Albemarle Company Profile
Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. Its Lithium segment offers lithium compounds, including lithium carbonate, lithium hydroxide, lithium chloride, and value-added lithium specialties, as well as reagents, such as butyllithium and lithium aluminum hydride for applications in lithium batteries for consumer electronics and electric vehicles, high performance greases, thermoplastic elastomers for car tires, rubber soles, plastic bottles, catalysts for chemical reactions, organic synthesis processes, life science, pharmaceutical, and other markets.
Further Reading: How does the Beige Book influence monetary policy?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.